Mayne Pharma is buying the North American rights to the leukemia drug Nipent and a medical surface cleaner from SuperGen for $15 million up front and up to $19 million in milestone payments. Mayne also says it is in talks to buy the cancer therapy mitmycin for the U.S. from SuperGen. "The addition of Nipent fits our strategy perfectly, building on our core oncology capability, particularly in the important US market," Mayne chief executive Dr Thierry Soursac said.
- read the report on the buyout from The Age